Resonance Health Limited

Equities

RHT

AU000000RHT2

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. 10:47:55 2024-03-27 pm EDT 5-day change 1st Jan Change
0.07 AUD +7.69% Intraday chart for Resonance Health Limited +11.11% +16.67%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Resonance Health Halts Trading Ahead of 'Material Acquisition' Announcement MT
Resonance Health Signs Collaboration Deal for Expansion Into Japanese Market MT
Resonance Health Changes Shareholder Registry Services Provider MT
Resonance Health Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Resonance Health Discloses 4.3% Reduction of Issued Shares MT
Resonance Health Appoints CFO MT
Resonance Health Ltd Appoints Benjamin Carruthers as Chief Financial Officer, Effective October 2023 CI
Resonance Health Limited Announces Resignation of Liesl Ellies as Joint Company Secretary CI
Resonance Health Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Resonance Health Secures Services Deal for Australian Clinical Trial MT
Resonance Health Limited Announces Resignation of Nick Allan as Chief Financial Officer CI
Resonance Health Limited Announces Resignation of Nick Allan as COO and Joint Company Secretary CI
Resonance Health Gets FDA Clearance to Market HepaFatSmart in US MT
Resonance Health Appoints CEO MT
Resonance Health Limited Announces CEO Changes CI
Resonance Health Ltd Appoints Aaron Brinkworth as Non-Executive Director CI
Resonance Health Limited Reports Earnings Results for the Half Year Ended December 30, 2022 CI
Resonance Health Files Patent for Liver Fibrosis Detection MT
Resonance Health Ltd Announces That It Has Lodged Provisional Patent Application in Relation to an Invention for the Detection and Assessment of Fibrosis in the Liver and Other Organ CI
Australian Shares Rally to More than Five-Month High as US Inflation Cools MT
Resonance Health Secures Two Services Contracts for Liver Iron Measuring Devices; Shares Jump 8% MT
Resonance Health Limited Announces Contracted for Two New Clinical Trials CI
Resonance Health Introduces Resonance Clinical MT
Resonance Health Launches Resonance Clinical CI
Resonance Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Chart Resonance Health Limited
More charts
Resonance Health Limited is an Australia-based MedTech company. The Company specializes in the development and delivery of non-invasive medical imaging software and services. The Company is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.
More about the company
  1. Stock
  2. Equities
  3. Stock Resonance Health Limited - Australian S.E.
  4. News Resonance Health Limited
  5. Resonance Health : Files Global Patent for Antisense Oligonucleotides Usage